Rectify Pharmaceuticals Inc., a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, has entered a strategic research and licensing agreement with Boehringer Ingelheim to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions. The collaboration leverages Rectify’s PFM platform to develop oral, small molecules that enhance ABCC6 protein function and reduce calcification, which is a key...